Abbisko Therapeutics Completed Dosing of First Patient for Its First-in-Class Highly Selective FGFR2/3 Inhibitor ABSK061

PR Newswire
July 4, 2022 — 13:34 CST

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!

Already have an account or paid subscription? Log in

Related Topics: China IPR pharmaceutical Shanghai stock market

Related News:

Harbour BioMed Announces Submission of IND Application for HBM9378/SKB378 in the Treatment of Chronic Obstructive Pulmonary Disease

November 8, 2024 — 17:45

Live from ESMO 2024 | Ascentage Pharma Releases Latest Data Showing Sustained Clinical Efficacy of Olverembatinib in SDH-Deficient GIST during a Mini Oral Presentation

September 14, 2024 — 08:18

Transcenta Holding Limited (Stock Code: 6628.HK) Announce 2024 Interim Results

August 29, 2024 — 14:31

LAZADA GROUP RELEASES ANNUAL ENVIRONMENTAL, SOCIAL AND GOVERNANCE (ESG) IMPACT REPORT FOR FINANCIAL YEAR 2024

August 27, 2024 — 11:00

Docquity and Vietnam Association of Preventive Medicine (VAPM) Partner to Advance Medical Training

August 21, 2024 — 10:00

2024 World Life Science Conference Scheduled for October 19 in Hainan, China

August 18, 2024 — 20:20

PRA Group Leader Wins Silver Stevie Award in 2024 International Business Awards

August 16, 2024 — 06:31

Viomi Technology Co., Ltd Enters Definitive Agreements to Divest Certain IoT@Home Businesses in an Effort to Strategically Focus on Home Water Solution Businesses

July 20, 2024 — 04:05

4 Days of Family Fun at Cotai Expo – Free-Admission Sands Shopping Carnival Open Now

July 19, 2024 — 13:45

Franchising and Licensing Asia (FLAsia) 2024